Tigermed Consulting signs alliance agreement with ICON

NewsGuard 100/100 Score

ICON (NASDAQ: ICLR)(ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and Tigermed Consulting, a leader in the provision of clinical drug development services in China, today announced that they have signed an alliance agreement.

“Tigermed has a substantial clinical operations presence on the Chinese mainland and this experience, gives them the ability to provide wide-ranging support for clinical drug development in China.”

Through this agreement, ICON and Tigermed will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilising the global reach and experience of the ICON organisation, complemented by Tigermed's in depth knowledge of the Chinese drug development landscape and geographic coverage in China. With headquarters in Shanghai, Tigermed currently operates from 21 offices in China and has over 300 clinical development staff located there.

"Tigermed has a substantial clinical operations presence on the Chinese mainland and this experience, gives them the ability to provide wide-ranging support for clinical drug development in China." commented Dr. John Hubbard, Group President, Global Clinical Research Services at ICON. " TigerMed's strength in China, complements ICON's strong regional presence in Asia Pacific and makes them the ideal partner for ICON as we continue to drive the rapid and effective development of our client's global drug development portfolios."

"We are extremely pleased to have signed this agreement with ICON" commented Xiaoping Ye, Chairman and CEO of Tigermed. "Not only are ICON recognised as a truly global provider of quality clinical services, their culture and core values built around people, performance and client focus fit well with those of Tigermed. This alliance enhances our regional and global capabilities and will enable both ICON and Tigermed to expand the range of clinical research services we can offer to clients in China and around the globe."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neurological Narratives: A Journey into Women's Brain Health Research